1. Mancia and Grassi (2018) Diabetologia DOI 10.1007/s00125-017-4537-3
Achieved SBP in randomised trials on type 2 diabetic individuals receiving antihypertensive treatment
FIGURE HERE
Mancia and Grassi (2018) Diabetologia DOI /s
© Wolters Kluwer Health/Lippincott Williams & Wilkins. Adapted from Zanchetti et al (2009)

2. Mancia and Grassi (2018) Diabetologia DOI 10.1007/s00125-017-4537-3
Effect of 10 mmHg reduction of SBP on outcomes in 40 trials on 100,354 diabetic individuals
Mancia and Grassi (2018) Diabetologia DOI /s
© Springer-Verlag GmbH Germany, part of Springer Nature 2017

3. Mancia and Grassi (2018) Diabetologia DOI 10.1007/s00125-017-4537-3
Risk (HR) and related level of statistical significance (p value) of outcomes in the subgroup of diabetic participants in the ACCORD trial who were randomised to intense (Int) or standard (Std) SBP reduction, following randomisation to intense or standard blood glucose reduction (which all trial participants underwent)
Mancia and Grassi (2018) Diabetologia DOI /s
© ADA. Adapted from Margolis et al (2014)

4. Mancia and Grassi (2018) Diabetologia DOI 10.1007/s00125-017-4537-3
SBP and DBP values in randomised clinical trials that have included exclusively, or a large number of type 2 diabetic patients
FIGURE HERE
Mancia and Grassi (2018) Diabetologia DOI /s
© Lippincott Williams & Wilkins. Adapted from Mancia and Grassi (2002)

5. Mancia and Grassi (2018) Diabetologia DOI 10.1007/s00125-017-4537-3
Serious adverse events attributed to antihypertensive treatment in the ACCORD study
FIGURE HERE
Mancia and Grassi (2018) Diabetologia DOI /s
© Springer-Verlag GmbH Germany, part of Springer Nature 2017